Maternal plasma soluble endoglin at 11-13 weeks' gestation in pre-eclampsia.


OBJECTIVES To examine the performance of screening for pre-eclampsia (PE) by a combination of maternal factors, soluble endoglin (sEng), pregnancy associated plasma protein-A (PAPP-A), placental growth factor (PlGF) and uterine artery lowest pulsatility index (L-PI) at 11-13 weeks' gestation. METHODS Uterine artery L-PI, sEng, PAPP-A and PlGF were… (More)
DOI: 10.1002/uog.7621


5 Figures and Tables

Slides referencing similar topics